Start for free
Start for free
ALSA Ventures logo

ALSA Ventures

Europe, England, United Kingdom, London

Description

ALSA Ventures invest in biotechnology companies passionate about bringing novel therapies to patients.

Investor Profile

ALSA Ventures has made 6 investments, with 1 in the past 12 months and 0% as lead.

Stage Focus

  • Seed (50%)
  • Series B (33%)
  • Series A (17%)

Country Focus

  • United Kingdom (67%)
  • Belgium (17%)
  • Bangladesh (17%)

Industry Focus

  • Biotechnology
  • Therapeutics
  • Oncology
  • Biopharma
  • Genetics
  • Life Science
  • Apps
  • Information Technology
  • Internet
  • Public Transportation
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does ALSA Ventures frequently co-invest with?

Pfizer Venture Investments
Pfizer Venture Investments
North America, New York, United States, New York
Co-Investments: 1
Novartis Venture Fund
Novartis Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 2
CP
Co-Investments: 1
Droia Ventures
Droia Ventures
Europe, Luxembourg, Luxembourg, Luxembourg
Co-Investments: 1
3B Future Health Fund
3B Future Health Fund
Europe, Bayern, Germany, Monaco
Co-Investments: 2
KU Leuven
KU Leuven
Europe, Vlaams-Brabant, Belgium, Leuven
Co-Investments: 1
British Patient Capital
British Patient Capital
Europe, Sheffield, United Kingdom, Sheffield
Co-Investments: 2
Schroders Capital
Schroders Capital
Europe, England, United Kingdom, London
Co-Investments: 1
Polaris Partners
Polaris Partners
North America, Massachusetts, United States, Boston
Co-Investments: 1
Epidarex Capital
Epidarex Capital
North America, Maryland, United States, Bethesda
Co-Investments: 2

What are some of recent deals done by ALSA Ventures?

Epsilogen

London, England, United Kingdom

Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.

BiopharmaBiotechnologyGeneticsLife ScienceOncologyTherapeutics
Series BSep 9, 2024
Amount Raised: $16,338,566
Vantage Biosciences

London, England, United Kingdom

Vantage Biosciences is a developer of an oral therapy designed for diabetic eye diseases.

BiotechnologyHealth CareProduct ResearchTherapeutics
SeedJul 19, 2023
Jatri

Dhaka, Dhaka, Bangladesh

EMPOWERING BANGLADESH TO TRAVEL BETTER

AppsInformation TechnologyInternetPublic TransportationReservationsRide SharingTicketingTransportation
Series AApr 15, 2023
Epsilogen

London, England, United Kingdom

Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.

BiopharmaBiotechnologyGeneticsLife ScienceOncologyTherapeutics
Series BMar 2, 2022
Amount Raised: $41,193,003
Promatix

London, England, United Kingdom

Promatix is a data-driven company that uses multi-omic information to develop the next generation of cancer therapeutics.

BiotechnologyPharmaceuticalTherapeutics
SeedMar 8, 2021
Montis Biosciences

Meise, Vlaams-Brabant, Belgium

Montis Biosciences is develops novel immune-oncology therapeutics targeting the intersection between vascular dysfunction.

BiotechnologyOncologyTherapeutics
SeedFeb 20, 2020
Amount Raised: $9,061,714
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsPricing

Free tools

Pre-Money and Post-Money Valuation Calculator